Health-care companies fell, but not by as much as the broad market, amid enthusiasm about a new class of drugs.
Shares of drug wholesaler Cardinal Health slipped despite reporting fiscal fourth-quarter earnings that surpassed Wall Street targets.
Cardinal boosted raised its full-year earnings projections, citing rising demand at its pharmaceutical unit, which makes and sources specialty products such as vaccines and antivirals.
Inotiv, a pharmaceutical testing company, faces an investigation into whether its monkey-sourcing practices may have violated U.S. anti-foreign bribery law.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
08-15-23 1716ET
